

"LINKING entrepreneurs to the region's wealth of resources is our number one priority. Accomplishing this goal will create more jobs, grow new businesses, and enrich our life sciences community."

**Barbara S. Schilberg, Managing Director/CEO**

## About BioAdvance

BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, was created as part of a \$2 billion initiative by the Commonwealth of Pennsylvania to stimulate the economy by supporting life sciences technologies and entrepreneurs. BioAdvance received \$33.8 million from the State's share of the national tobacco settlement to accelerate the creation of life sciences jobs and businesses in Southeastern Pennsylvania. BioAdvance's mission is to transform the region's strengths in biomedical research and development into commercial opportunities.

*To fulfill its mission, BioAdvance is:*

- Investing in emerging life science technologies with the most promising commercialization prospects.
- Working to accelerate the transfer of technology from research laboratories to start-ups and emerging companies.
- Building collaborations between academic, entrepreneurial, corporate, financial and government partners.
- Developing ways to attract, retain and support life sciences entrepreneurs.

BioAdvance is accomplishing these goals through its \$20 million key funding program, the Greenhouse Fund, and other initiatives to link entrepreneurs to the region's wealth of resources. BioAdvance also launched the Greater Philadelphia BioInformatics Alliance, is establishing an innovative clinical trial network, and has sponsored a \$20-40 million early-stage life science venture fund that will be managed by Quaker BioVentures, a leading venture capital firm headquartered in Philadelphia.

## About the Greenhouse Fund

BioAdvance supports early stage projects that have the potential to improve people's lives and enhance the region's life sciences community. BioAdvance created the Greenhouse Fund to help move commercially promising therapeutics, medical devices and discovery technologies from the laboratory to the stage where venture capital or corporate funding sources become available. To date, BioAdvance has selected the following early stage recipients to receive up to \$6 million for these projects:

**Acuity Pharmaceuticals, Inc.** [www.acuitypharma.com](http://www.acuitypharma.com)

Dale Pfof, Ph.D., Chairman, President & CEO

Acuity is moving cutting-edge RNA interference technology discovered at the University of Pennsylvania into clinical trials to treat the leading causes of adult blindness.

**Alteris Therapeutics, Inc.** [www.alteristhera.com](http://www.alteristhera.com)

Albert Wong, M.D., CSO

Alteris, formerly called Spliceomix, Inc., is focused on the discovery and development of therapeutics and vaccines against novel, proprietary cancer targets.

**BioSensus, LLC** Email: [j.yasha.kresh@drexel.edu](mailto:j.yasha.kresh@drexel.edu)

J. Yasha Kresh Ph.D., Co-founder & Chief BioMedical Officer

BioSensus, out of Drexel University, is pioneering miniaturized acoustic sensing devices for rapid, on-site and patient self-testing, initially to measure blood clotting time and platelet function.

**Cira Discovery Sciences, Inc.** [www.ciradiscovery.com](http://www.ciradiscovery.com)

Wade T. Rogers, Ph.D., President & CEO

Cira discovers patterns of biomarkers for diagnostics and drug discovery using its proprietary computational platform.

**Eagle Vision Pharmaceuticals, Inc.** [www.eaglevpc.com](http://www.eaglevpc.com)

Philip P. Harnish, Ph.D., Chairman & CEO

Eagle Vision focuses on the discovery and development of novel diagnostic imaging agents designed to enhance Magnetic Resonance Imaging's (MRI) powerful potential for diagnosis and management of heart disease, liver disease and cancer to replace the more limited, costly and invasive procedures currently used.

**Gelifex, Inc.** [www.synthes-stratec.com](http://www.synthes-stratec.com)

Alastair Clemow, Ph.D., CEO

Gelifex was formed in June 2002 to develop novel spine implants for use in relieving pain and restoring motion to patients suffering from degenerative disc disease of the lower back. In April 2004, Gelifex was acquired by Synthes, Inc., a multinational medical device company located in Suburban Philadelphia.

**LumenVu** [www.lumenvu.com](http://www.lumenvu.com)

Elizabeth Poppert, Ph.D., Director, Licensing Physical Sciences, University of Pennsylvania

LumenVu, out of the University of Pennsylvania, is embedding lights in catheters to direct their accurate placement in the body.

**MacroArray Technologies, Inc.** Email: [mjwassil@aol.com](mailto:mjwassil@aol.com)

Michael Wassil, CEO/COO

MacroArray is an early stage biotechnology company using DNA array technology and a novel proteomics-based platform to develop novel diagnostic markers and therapeutics for a variety of cancers. Their lead product is a urine-based test for prostate cancer.

**PhenoTech, Inc.** Email: [maestre@phenotech.com](mailto:maestre@phenotech.com)

Guy Maestre, President & CEO

Phenotech, out of the University of Pennsylvania, is employing novel molecular technology to develop a new class of renewable, inexpensive, high-quality blood bank testing reagents that will function in a rapid, high-throughput, automatable assay system.

**Protez Pharmaceuticals, Inc.** [www.protez.com](http://www.protez.com)

Christopher M. Cashman, CEO

Protez is developing novel antibiotics to combat drug resistance in difficult-to-treat hospital-based infections.

**RetinaPharma Technologies, Inc.** [www.retinapharma.com](http://www.retinapharma.com)

Terry A. Fuller, Ph.D., President & CEO

RetinaPharma is developing products for the prevention, treatment and diagnosis of vision disorders and neural diseases that affect over 19.5 million people in the United States and Western Europe.

**TheraQuest Biosciences, LLC** [www.theraquestinc.com](http://www.theraquestinc.com)

Najib Babul, PharmD, CEO & CSO

TheraQuest, an analgesic specialist, is developing four novel products for the treatment of moderate-to-severe pain conditions.

**Yaupon Therapeutics, Inc.** [www.yaupontherapeutics.com](http://www.yaupontherapeutics.com)

Robert Alonso, President & CEO

Yaupon is identifying valuable pharmaceuticals by applying 21st century know-how to plants with medicinal value, with its lead product entering clinical trials as the first drug for treatment of methamphetamine addiction.